Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-07-22Clinical Trial Update: Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
A long-term follow-up update on patients previously treated with Mustang Bio's CAR-T cell investigational product; the trial has been termin…
-
CLINICAL_TRIALS trial_result · 2024-07-18Clinical Trial Update: A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma [Phase 1, Phase 2]
MS-553 trial in relapsed/refractory B-cell lymphomas was terminated after Phase 1/2 studies.
-
CLINICAL_TRIALS trial_result · 2024-07-16Clinical Trial Update: A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) [Phase 2]
Phase 2 clinical trial update on LOXO-305 (pirtobrutinib) in Chinese participants with B-cell malignancies, with results posted on July 16, …
-
CLINICAL_TRIALS trial_result · 2024-07-11Clinical Trial Update: A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 1]
This Phase 1 clinical trial update assesses venetoclax with polatuzumab vedotin, rituximab, and CHP in untreated BCL-2 IHC-positive diffuse …
-
CLINICAL_TRIALS trial_result · 2024-07-09Clinical Trial Update: FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL [Phase 1]
Phase 1 trial results for FT596 CAR-T cells with Rituximab as relapse prevention after autologous HSCT in non-Hodgkin lymphoma were posted, …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-07-09Clinical Trial Update: Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas [Phase 1]
Phase 1 trial evaluating copanlisib with dose-adjusted EPOCH-R in relapsed and refractory Burkitt lymphoma and other high-grade B-cell lymph…
-
CLINICAL_TRIALS trial_result · 2024-07-01Clinical Trial Update: R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating R-ICE chemotherapy in combination with lenalidomide for patients with first-relapse or primary refractory diffuse…
-
CLINICAL_TRIALS trial_result · 2024-06-27Clinical Trial Update: Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) [Phase 1]
Phase 1 study evaluating safety and pharmacokinetics of JCAR017 in B-cell non-Hodgkin lymphomas has completed.
-
CLINICAL_TRIALS trial_result · 2024-06-13Clinical Trial Update: A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies [Phase 1]
Phase Ib study of YY-20394 in participants with B-cell hematologic malignancies has completed, evaluating safety and preliminary activity ac…
-
CLINICAL_TRIALS trial_result · 2024-06-11Clinical Trial Update: Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies [Phase 1]
Phase 1 study of STRO-001, an anti-CD74 antibody-drug conjugate, in advanced B-cell malignancies has been completed.
-
CLINICAL_TRIALS trial_result · 2024-05-30Clinical Trial Update: A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin [Phase 2]
Phase 2 trial comparing pixantrone against doxorubicin in patients with diffuse large B-cell lymphoma has completed and results have been po…
-
CLINICAL_TRIALS trial_result · 2024-05-30Clinical Trial Update: Imaging Apoptosis for Lymphoma Treatment Response [EARLY_Phase 1]
A Phase 1 trial evaluating imaging apoptosis to monitor treatment response in Diffuse Large B Cell Lymphoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-05-29Clinical Trial Update: Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma [Phase 1, Phase 2]
This trial result updates a Phase 1/2 study evaluating carfilzomib with rituximab and a chemotherapy regimen in adults with diffuse large B-…
-
CLINICAL_TRIALS trial_result · 2024-05-20Clinical Trial Update: A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]
This is a Phase 1 study update for CC-97540, a CD19-targeted NEX-T CAR T cell therapy, in relapsed or refractory B-cell non-Hodgkin lymphoma…
-
CLINICAL_TRIALS trial_result · 2024-05-17Clinical Trial Update: Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL [Phase 2]
Phase 2 study evaluating Debio 1562 in combination with Rituximab for relapsed/refractory Diffuse Large B-Cell Lymphoma and other B-cell non…
-
CLINICAL_TRIALS trial_result · 2024-05-13Clinical Trial Update: Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients [Phase 2]
Phase 2 trial evaluating lenalidomide combined with R-CHOP (R2-CHOP) for newly diagnosed double-expressor diffuse large B-cell lymphoma has …
-
CLINICAL_TRIALS trial_result · 2024-05-13Clinical Trial Update: A Study of ICP-022 in Patients With R/R DLBCL [Phase 2]
Phase 2 study of ICP-022 in relapsed/refractory diffuse large B cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2024-05-13Clinical Trial Update: Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS [Phase 2]
This Phase 2 trial investigates reduction of methotrexate levels after glucarpidase treatment in Diffuse Large B-Cell Lymphoma patients at r…
-
CLINICAL_TRIALS trial_result · 2024-05-02Clinical Trial Update: Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma [Phase 1]
A Phase 1 study evaluating the safety and preliminary efficacy of the combination of duvelisib and nivolumab in patients with Richter syndro…
-
CLINICAL_TRIALS trial_result · 2024-04-30Clinical Trial Update: Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL) [Phase 2]
Phase 2 trial evaluating plamotamab plus tafasitamab and lenalidomide versus tafasitamab and lenalidomide in relapsed or refractory diffuse …
-
CLINICAL_TRIALS trial_result · 2024-04-18Clinical Trial Update: Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients [Phase 2]
Phase 2 trial update on CTL019 (tisagenlecleucel) for adult diffuse large B-cell lymphoma; results posted after completion.
-
CLINICAL_TRIALS trial_result · 2024-04-09Clinical Trial Update: Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma [Phase 2]
Phase 2 trial evaluating lenalidomide as maintenance therapy in relapsed diffuse large B-cell lymphoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2024-04-09Clinical Trial Update: Maintenance Hormonal Therapy and DLBCL [Phase 2, Phase 3]
Phase 2/3 clinical trial update evaluating maintenance hormonal therapy for Diffuse Large B-Cell Lymphoma.
-
CLINICAL_TRIALS trial_result · 2024-03-27Clinical Trial Update: R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL [Phase 3]
Phase 3 trial comparing R-DA-EDOCH versus R-CEOP90 with/without upfront autologous HSCT in young high-risk diffuse large B-cell lymphoma pat…
-
CLINICAL_TRIALS trial_result · 2024-03-25Clinical Trial Update: A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma [Phase 1]
Phase 1 study evaluating safety and efficacy of Glofitamab or Mosunetuzumab with gemcitabine plus oxaliplatin in relapsed/refractory B-cell …